STOCK TITAN
  1. Home
  2. Sec-filings
  3. CCTC
  4. [10-Q] LataMed AI Corp. Quarterly Earnings Report

LataMed AI Corp. (CCTC) posts Q1 loss, no revenue amid AI healthcare pivot

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
10-Q

Rhea-AI Filing Summary

LataMed AI Corp. reported a net loss of $52,813 for the quarter ended March 31, 2026, with no revenue, as it shifted toward AI-enabled healthcare technology and services in Latin America. The company recorded intangible assets of $7,824,000, primarily from an asset purchase paid in shares, but reported no cash.

Current liabilities were $683,673, resulting in a working capital deficit of the same amount and an accumulated deficit of $29,653,599. Management disclosed that these conditions raise substantial doubt about its ability to continue as a going concern and is relying on 10% promissory notes and other financing to fund operations. Disclosure controls were deemed not effective due to limited internal resources.

Positive

  • None.

Negative

  • Going concern uncertainty: Management states that recurring losses of $52,813 for Q1 2026, an accumulated deficit of $29,653,599, no cash, and reliance on external financing raise substantial doubt about the Company’s ability to continue as a going concern.
  • Highly leveraged, intangible-heavy balance sheet: As of March 31, 2026 the Company reported $7,824,000 in intangible assets, current liabilities of $683,673, notes payable of $300,688 plus $34,591 in convertible notes, and a working capital deficit of $683,673.
  • Weak internal controls: The Company’s CEO and CFO concluded disclosure controls and procedures were not effective as of March 31, 2026 due to limited internal resources and lack of multiple levels of transaction review.

Insights

Early-stage pivot with no cash and a disclosed going concern risk.

LataMed AI Corp. is effectively a pre-revenue shell pivoting into AI-enabled healthcare in Latin America. Q1 2026 revenue was zero, while the company booked a net loss of $52,813 and capitalized $7,824,000 of intangible assets from a recent asset purchase paid in stock.

The balance sheet is highly stressed: there was no cash at quarter-end, current liabilities totaled $683,673, and the accumulated deficit reached $29,653,599. Management explicitly states that these factors raise substantial doubt about continuing as a going concern and notes full dependence on external funding, including 10% demand notes and related-party debt of $88,042.

Governance and capital structure are evolving, with recent leadership changes, a 1-for-450 reverse stock split, and subsequent designation of non-convertible Series C Voting Preferred Stock carrying twenty votes per share. Future filings will be important to see whether the AI healthcare strategy begins generating revenue and whether new equity or debt financing alters the company’s leverage and control dynamics.

Net loss $52,813 For the three months ended March 31, 2026
Revenue $0 For the three months ended March 31, 2026 and 2025
Intangible assets $7,824,000 Balance sheet as of March 31, 2026
Current liabilities $683,673 Balance sheet as of March 31, 2026
Working capital deficit $683,673 As of March 31, 2026
Notes payable $300,688 Promissory notes outstanding as of March 31, 2026
Convertible notes payable $34,591 Outstanding as of March 31, 2026
Accumulated deficit $29,653,599 As of March 31, 2026
going concern financial
"These conditions raise substantial doubt about the Company's ability to continue as a going concern."
A going concern is a business that is expected to continue its operations and meet its obligations for the foreseeable future, rather than shutting down or selling off assets. This assumption matters to investors because it indicates stability and ongoing profitability, making the business a more reliable investment. Think of it as believing a restaurant will stay open and serve customers, rather than closing down suddenly.
Asset Purchase Agreement financial
"On February 17, 2026, the Company entered into an Asset Purchase Agreement pursuant to which it acquired various proprietary assets and intellectual property"
An asset purchase agreement is a legal contract in which a buyer agrees to buy specific assets and contracts of a business rather than buying the company’s stock or ownership. It matters to investors because it determines exactly what is being bought and what liabilities stay behind — like buying the furniture and equipment from a store but not the building or past debts — which affects the deal’s value, taxes and future risk exposure.
reverse stock split financial
"On July 1, 2024, the Company’s Board of Directors approved a One for Four Hundred Fifty (1-for-450) Reverse Stock Split"
A reverse stock split is when a company reduces the number of its shares outstanding, making each share more valuable. For example, if you own 100 shares worth $1 each, a 1-for-10 reverse split would turn your 100 shares into 10 shares worth $10 each. Companies often do this to boost their stock price and appear more stable to investors.
Series C Voting Preferred Stock financial
"the Board of Directors of the Company approved the designation of a new series of preferred stock designated as the "Series C Voting Preferred Stock""
telehealth infrastructure technical
"technologies intended to support data-driven healthcare analytics, patient monitoring, telehealth infrastructure, and related healthcare applications."
disclosure controls and procedures regulatory
"the Company conducted an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures"
Policies, routines and internal checks a public company uses to identify, collect and verify information that must appear in its financial reports and public filings, and to make sure that material news is disclosed accurately and on time. Investors care because effective controls increase confidence that the company’s reported numbers and disclosures are reliable and reduce the risk of surprises, much like a building’s inspection and alarm system helps occupants trust the structure’s safety.
10-Q Quarterly Reports: What Changes Quarter to Quarter →

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Quarterly Period Ended: March 31, 2026

 

OR

 

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Transition Period From ____________ to ____________.

 

LATAMED AI CORP.

(Exact name of registrant as specified in its charter)

 

  Nevada

 

000-52543

 

26-3670551

(State or other jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

Av. Rómulo Gallegos con Av. Las Palmas

Edif. Torre Gerencial Los Andes

Caracas 1071, Venezuela

(Address of principal executive offices, including zip code.)

 

+1 787 476 2350 

(Telephone number, including area code)

 

Securities registered under Section 12(b) of the Act: None

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒    No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒    No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer 

☐

Accelerated filer

☐

Non-accelerated filer

☒

Smaller reporting company

☒

 

 

Emerging growth company

☒

 

If an emerging growth company, indicate by check mark if the Company has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☒

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐    No ☒

 

As of May 15, 2026, the registrant had 56,134,795 shares of common stock issued and outstanding.

 

 

 

 

 

LATAMED AI CORP.

 FORM 10-Q

 

Index

 

PART I. FINANCIAL INFORMATION

 

 

 

 

 

 

 

 

Item 1.

Condensed Financial Statements.

 

4

 

 

CONDENSED BALANCE SHEETS

 

4

 

 

CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED)

 

5

 

 

CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)

 

7

 

 

CONDENSED STATEMENT OF CHANGES IN STOCKHOLDERS’ EQUITY (UNAUDITED)

 

6

 

 

NOTES TO CONDENSED FINANCIAL STATEMENTS (UNAUDITED)

 

8

 

Item 2.

Management’s Discussion and Analysis of Financial Conditions and Results of Operations.

 

15

 

Item 3.

Quantitative and Qualitative Disclosures about Market Risk.

 

16

 

Item 4.

Controls and Procedures.

 

16

 

 

 

 

 

 

PART II. OTHER INFORMATION

 

 

 

 

 

 

 

 

Item 5.

Other Information.

 

17

 

Item 6.

Exhibits.

 

18

 

 

 
2

Table of Contents

 

SPECIAL NOTE REGARDING FORWARD-LOOKING INFORMATION

 

This quarterly report on Form 10-Q and other publicly available documents, including the documents incorporated herein by reference, contain, and our officers and representatives may from time to time make, “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “believe,” “expect,” “future,” “likely,” “may,” “plan,” “seek,” “will” and similar references to future periods actions or results. Examples of forward-looking statements include our prospects for one or more future material transactions, potential sources of financing, and expenses for future periods.

 

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.

 

Any forward-looking statement made by us in this quarterly report on Form 10-Q is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

 

Factors that could cause or contribute to such differences may include, but are not limited to, those described under the heading “Risk Factors” which may be included in the Company’s Registration Statement on Form 10 as previously filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. The Company undertakes no obligation to revise any forward-looking statements in order to reflect events or circumstances that may subsequently arise. Readers are urged to carefully review and consider the various disclosures made by the Company in this report and in the Company’s other reports filed with the Commission that advise interested parties of the risks and factors that may affect the Company’s business. 

 

 
3

Table of Contents

 

PART I. FINANCIAL INFORMATION

 

Item 1. Condensed Financial Statements.

 

LataMed AI Corp.

(FKA Catalyst Crew Technologies Corp.)

CONDENSED BALANCE SHEETS

(Unaudited)

 

 

 

March 31, 2026

 

 

December 31, 2025

 

ASSETS

 

 

 

 

 

 

Current assets

 

 

 

 

 

 

Cash

 

$-

 

 

$-

 

Total current assets

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Intangible assets

 

 

7,824,000

 

 

 

-

 

 

 

 

 

 

 

 

 

 

 Total assets

 

 

7,824,000

 

 

 

-

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' DEFICIT

 

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

 

 

Accounts payable and accrued liabilities

 

 

260,352

 

 

 

235,923

 

Notes payable - related party

 

 

88,042

 

 

 

88,042

 

Notes payable

 

 

300,688

 

 

 

272,304

 

Convertible notes payable

 

 

34,591

 

 

 

34,591

 

Total current liabilities

 

 

683,673

 

 

 

630,860

 

 

 

 

 

 

 

 

 

 

Total liabilities

 

 

683,673

 

 

 

630,860

 

 

 

 

 

 

 

 

 

 

Stockholders' deficit

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Preferred stock, $0.0001 par value, 280,000,000 shares authorized, 0 and 0 and shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Series A Preferred stock, $0.0001 par value, 20,000,000 shares authorized, 0 and 0 and shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Series B Preferred stock, $0.0001 par value, 20,000,000 shares authorized, 0 and 0 and shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively

 

 

-

 

 

 

-

 

 

 

 

 

 

 

 

 

 

Common stock, $0.0001 par value, 700,000,000 shares authorized, 243,632 and 243,632 and shares issued and outstanding as of March 31, 2026 and December 31, 2025

 

 

56,136

 

 

 

44,298

 

Additional paid in capital

 

 

36,737,790

 

 

 

28,925,628

 

Accumulated deficit

 

 

(29,653,599)

 

 

(29,600,786)

Total stockholders' deficit

 

 

7,140,327

 

 

 

(630,860)

 

 

 

 

 

 

 

 

 

Total liabilities and stockholders' deficit

 

$7,824,000

 

 

$-

 

 

 See accompanying notes to the financial statements

 

 
4

Table of Contents

 

LataMed AI Corp.

(FKA Catalyst Crew Technologies Corp.)

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

 

 

 

 For the three months ended 

 

 

 

March 31, 2026

 

 

March 31, 2025

 

 

 

 

 

 

 

 

Revenue

 

$-

 

 

$-

 

 

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

 

General and administrative

 

 

9,187

 

 

 

967

 

Professional fees

 

 

34,197

 

 

 

15,000

 

Total operating expenses

 

 

43,384

 

 

 

15,967

 

 

 

 

 

 

 

 

 

 

Loss from operations

 

 

(43,384)

 

 

(15,967)

 

 

 

 

 

 

 

 

 

Other income (expenses)

 

 

 

 

 

 

 

 

Interest expense

 

 

(9,429)

 

 

(8,488)

Total other expenses

 

 

(9,429)

 

 

(8,488)

 

 

 

 

 

 

 

 

 

Net loss before tax provision

 

 

(52,813)

 

 

(24,455)

Tax provision

 

 

-

 

 

 

-

 

Net loss

 

$(52,813)

 

$(24,455)

 

 

 

 

 

 

 

 

 

Net loss per common share - basic and diluted

 

$(0.00)

 

$(0.00)

 

 

 

 

 

 

 

 

 

Weighted average number of common shares outstanding - basic and diluted

 

 

56,134,795

 

 

 

29,276,895

 

 

  See accompanying notes to the financial statements

 

 
5

Table of Contents

 

LataMed AI Corp.

(FKA Catalyst Crew Technologies Corp.)

 CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Total 

 

 

 

 Common Stock

 

 

 Additional

 

 

 Accumulated

 

 

    Stockholders' 

 

 

 

 Shares

 

 

 Amount

 

 

 Paid-in Capital

 

 

 Deficit

 

 

   Deficit

 

Balance, December 31, 2025

 

 

44,296,895

 

 

 

44,298

 

 

 

28,925,628

 

 

 

(29,600,786)

 

 

(630,860)

Shares issued for asset purchase agreement

 

 

12,000,000

 

 

 

12,000

 

 

 

7,812,000

 

 

 

-

 

 

 

7,824,000

 

Shares returned and cancelled

 

 

(162,100)

 

 

(162)

 

 

162

 

 

 

-

 

 

 

-

 

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(52,813)

 

 

(52,813)

Balance, March 31, 2026

 

 

56,134,795

 

 

 

56,136

 

 

 

36,737,790

 

 

 

(29,653,599)

 

 

7,140,327

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance, December 31, 2024

 

 

29,276,895

 

 

 

29,278

 

 

 

28,790,448

 

 

 

(29,393,301)

 

 

(573,575)

Net loss

 

 

-

 

 

 

-

 

 

 

-

 

 

 

(24,455)

 

 

(24,455)

Balance, March 31, 2025

 

 

29,276,895

 

 

 

29,278

 

 

 

28,790,448

 

 

 

(29,417,756)

 

 

(598,030)

 

  See accompanying notes to the financial statements

 

 
6

Table of Contents

 

LataMed AI Corp.

(FKA Catalyst Crew Technologies Corp.)

  CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)

 

 

 

 For the three months ended 

 

 

 

March 31, 2026

 

 

March 31, 2025

 

Cash Flows from Operating Activities

 

 

 

 

 

 

Net loss

 

$(52,813)

 

$(24,455)

Adjustments to reconcile net loss to net cash provided by operating activities:

 

 

 

 

 

 

 

 

Changes in assets and liabilities

 

 

 

 

 

 

 

 

Accounts payable and accrued liabilities

 

 

24,429

 

 

 

5,440

 

Net cash used in continuing operating activities

 

 

(28,384)

 

 

(19,015)

 

 

 

 

 

 

 

 

 

Cash Flows from Financing Activities:

 

 

 

 

 

 

 

 

Proceeds from notes payable

 

 

28,384

 

 

 

19,015

 

Net cash provided by financing activities

 

 

28,384

 

 

 

19,015

 

 

 

 

 

 

 

 

 

 

Net decrease in cash

 

 

-

 

 

 

-

 

Cash, beginning of period

 

 

-

 

 

 

-

 

Cash, end of period

 

$-

 

 

$-

 

 

 

 

 

 

 

 

 

 

Supplemental disclosure of cash flow information

 

 

 

 

 

 

 

 

Cash paid for interest

 

$-

 

 

$-

 

Cash paid for taxes

 

$-

 

 

$-

 

 

 

 

 

 

 

 

 

 

SUPPLEMENTARY DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Shares issued for intangible assets

 

$-

 

 

$875,000

 

 

  See accompanying notes to the financial statements

 

 
7

Table of Contents

 

LataMed AI Corp.

(FKA Catalyst Crew Technologies Corp.)

NOTES TO FINANCIAL STATEMENTS

MARCH 31, 2026

 

NOTE 1 – NATURE OF BUSINESS AND OPERATIONS

 

Organization

 

LataMed AI Corp.(FKA Catalyst Crew Technologies Corp.) (the “Company or “CBBB”) was incorporated in the State of Nevada on September 11, 2008. At that time the primary business of the Company was to act as a global broker for business and private jets by connecting travelers (corporations, institutions and wealthy private individuals) with executive aircraft that are independently owned and operated by third party companies or individuals. On February 5, 2015, the Company changed its name to better reflect its anticipated new business direction. The Company had received approval of its Federal Permit to distribute alcoholic beverages, which would be accomplished, through its subsidiaries, Continental Beverage Inventory and Warehousing Ltd., and promotional activities through Continental Beverage Marketing and Promotion Inc. In early 2016, the Company abandoned its activities and ceased to operate.

 

On March 20, 2023, the “Company entered into an Asset Purchase Agreement by and among the Company, on the one hand and JT Technologies LLC (“JTLLC”) and Nitish Sharma, an individual and the sole managing member of JTLLC, on the other hand whereby the Company acquired various big data analytics related assets from the Seller for use in the gaming and gambling industry to analyze player behavior and fraud protection, among other similar information. Collectively, al intellectual property, proprietary and non-proprietary technology, know-how, and all other assets of the seller that maybe, directly, or indirectly, applied to big data analytics in the gaming and gaming industry are referred to hereinafter as the “Acquired Assets”. In exchange for the Acquired Assets, the Company issued 5,000,000 restricted shares of the 2. Buyer’s common stock to Seller.

 

On May 26, 2023, the Company changed its name to Blue Chip Technologies Corporation.

 

On September 18, 2023, the Company received notice of resignation from Mr. Andrew Gaudet from the positions of President, Chief Executive Officer, Treasurer, Chief Financial Officer, and Secretary. Mr. Gaudet retained his position as a member of the Company’s Board of Directors.

 

Effective the same day, the Company entered into an Executive Employment with Gurneet Kaur whereby Ms. Kaur agreed to serve as the Company’s Chief Executive Officer, President, Chief Financial Officer, Treasurer, Secretary, and as Chairman of the Company’s Board of Directors. On the same day, and pursuant to a Stock Purchase Agreement, Ms. Kaur acquired 48,944,965 shares of common stock from Nitish Sharma. Accordingly, Ms. Kaur now owns 72,944,965 restricted shares of our common stock, which represents approximately 66.53% of the total issued and outstanding shares of common stock.

 

On June 5, 2024, Ms. Kaur sold, by way of Stock Purchase Agreement (the “SPA”), 72,944,965 restricted shares of the Company’s common stock to Waqas Nakhwa. As a result of this SPA, Nakhwa is now deemed our controlling shareholder by virtue of his purchase of the Shares and holds 66.53% of our total voting stock.

 

Additionally, on June 7, 2024, the Company received notice of resignation from Ms. Kaur from the positions of President, Chief Executive Officer, Treasurer, Chief Financial Officer, Secretary and Director of the Company. Ms. Kaur’s resignation was not the result of any disagreements between Ms. Kaur and the Company relating to the Company’s operations, policies, or practices.

 

Effective immediately upon the resignation of Ms. Kaur, the Company’s Board of Directors appointed Mr. Nakhwa to serve as President, Chief Executive Officer, Treasurer, Chief Financial Officer, Secretary and Chairman of the Board of Directors to serve until the next annual meeting of the Company or until his respective successor is duly appointed. Mr. Nakhwa accepted all such appointments, effective as of June 7, 2024.

 

 
8

Table of Contents

 

 

On June 9, 2024, the Company entered into an Asset  Transfer Agreement with Mr. Nakhwa pursuant to which Mr. Nakhwa assigned to the Company all of Mr. Nakhwa’s interest in Facial Recognition Technology (FRT) solutions and intellectual property associated therewith in exchange for $1.00.

 

On June 11, 2024, as a result of this change in management, the Company’s Board of Directors voted to (i) cease all prior operations of the Company involving big data analytics software for use in the gaming and financial technology industries, (ii) relinquish and disavow any and all interest in existing subsidiaries as of June 11, 2024 and (iii) amend the Company’s Articles of Incorporation to change the name of the Company to “Catalyst Crew Technologies Corp.” to more accurately reflect the Company’s new business direction.  The Company will endeavor to affect the name change in near future or at such time management deems the name change appropriate. In the interim period until we affect this proposed name change, we will be operating as “Catalyst Crew Technologies.

 

On July 1, 2024, the Company’s Board of Directors approved a Change to its Articles of Incorporation, as amended, with the Secretary of Nevada to change the Company’s corporate name to “Catalyst Crew Technologies Corp.”

 

On February 17, 2026, the Company appointed Kevin Rodan Levy to serve as Chief Executive Officer, President, Chief Financial Officer, Secretary, Treasurer, and sole board member of the Company, effective immediately. On April 28, 2026, the Company filed a Certificate of Amendment with the Nevada Secretary of State changing the Company’s corporate name to "LataMed AI Corp.," which became effective upon filing.

 

On March 31, 2026, the Company's Board of Directors appointed Carlos Peña as Chief Financial Officer of the Company, effective immediately. Mr. Peña replaced Kevin Rodan Levy in the CFO role. Mr. Rodan Levy continues to serve as Chief Executive Officer, President, Secretary, Treasurer, and sole Director of the Company.

 

BASIS OF PRESENTATION

 

The accompanying financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States. Management is of the opinion that all necessary adjustments have been made to make these interim financial statements not misleading.

  

NOTE 2 – GOING CONCERN

 

The accompanying financial statements have been prepared in US dollars and in accordance with accounting principles generally accepted in the United States (“GAAP”) on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. During three months ended March 31, 2026, the Company incurred net losses of $52,813 and accumulated deficits of $29,653,599. These conditions raise substantial doubt about the Company's ability to continue as a going concern.

 

We are entirely dependent on our ability to attract and receive funding from either the sale of securities or outside sources such as private investment or a strategic partner. We currently have no firm agreements or arrangements with respect to any such financing and there can be no assurance that any needed funds will be available to us on acceptable terms or at all. The inability to obtain sufficient funding of our operations in the future will restrict our ability to grow and reduce our ability to continue to conduct business operations. Our failure to raise additional funds will adversely affect our business, and may require us to suspend our operations, which in turn may result in a loss to the purchasers of our common stock. If we are unable to obtain necessary financing, we will likely be required to curtail our development plans. Any additional equity financing may involve substantial dilution to our then existing stockholders.

 

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Use of Estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ significantly from those estimates.

 

 
9

Table of Contents

 

 

Cash and Cash Equivalents

For purposes of the statement of cash flows, the Company considers all highly liquid debt instruments purchased with a maturity of three months or less to be cash equivalents to the extent the funds are not being held for investment purposes.

 

Stock-based compensation

The Company follows ASC 718-10, “Stock Compensation”, which addresses the accounting for transactions in which an entity exchanges its equity instruments for goods or services, with a primary focus on transactions in which an entity obtains employee services in share-based payment transactions. ASC 718-10 is a revision to SFAS No. 123, “Accounting for Stock-Based Compensation,” and supersedes Accounting Principles Board (“APB”) Opinion No. 25, “Accounting for Stock Issued to Employees,” and its related implementation guidance. ASC 718-10 requires measurement of the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair value of the award (with limited exceptions). Incremental compensation costs arising from subsequent modifications of awards after the grant date must be recognized.

 

Concentration of Credit Risk

The Company has no off-balance-sheet concentrations of credit risk such as foreign exchange contracts, options contracts or other foreign hedging arrangements. The Company maintains all of its cash balances with two financial institutions in the form of demand deposits.

 

Earnings per share

The Company follows ASC Topic 260 to account for the earnings per share. Basic earnings per common share (“EPS”) calculations are determined by dividing net income by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation.

 

Revenue Recognition

The Company recognizes revenue from its contracts with customers in accordance with ASC 606 – Revenue from Contracts with Customers. The Company recognizes revenues when satisfying the performance obligation of the associated contract that reflects the consideration expected to be received based on the terms of the contract.

 

Revenue related to contracts with customers is evaluated utilizing the following steps: (i) Identify the contract, or contracts, with a customer; (ii) Identify the performance obligations in the contract; (iii) Determine the transaction price; (iv) Allocate the transaction price to the performance obligations in the contract; (v) Recognize revenue when the Company satisfies a performance obligation.

 

Fair Value of Financial Instruments

The Company measures fair value in accordance with ASC 820 - Fair Value Measurements. ASC 820 defines fair value and establishes a three-level valuation hierarchy for disclosures of fair value measurements. ASC 820 establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. To increase consistency and comparability in fair value measurements and related disclosures, ASC 820 establishes a fair value hierarchy which prioritizes the inputs to valuation techniques used to measure fair value into three (3) broad levels. The fair value hierarchy gives the highest priority to quoted prices (unadjusted) in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The three (3) levels of fair value hierarchy defined by ASC 820 are:

 

Level 1 - Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.

 

Level 2 - Inputs (other than quoted market prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.

 

Level 3 - Inputs reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. Valuation of instruments includes unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities.

 

 

 
10

Table of Contents

 

As defined by ASC 820, the fair value of a financial instrument is the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale, which was further clarified as the price that would be received to sell an asset or paid to transfer a liability (“an exit price”) in an orderly transaction between market participants at the measurement date

 

The reported fair values for financial instruments that use Level 2 and Level 3 inputs to determine fair value are based on a variety of factors and assumptions. Accordingly, certain fair values may not represent actual values of the Company’s financial instruments that could have been realized as of March 31, 2025 and December 31, 2024 or that will be recognized in the future, and do not include expenses that could be incurred in an actual settlement. The carrying amounts of the Company’s financial assets and liabilities, such as cash, accounts receivable, receivables from related parties, prepaid expenses and other, accounts payable, accrued liabilities, and related party and third-party notes payables approximate fair value due to their relatively short maturities. The Company’s notes payable approximates the fair value of such instrument based upon management’s best estimate of terms that would be available to the Company for similar financial arrangements on March 31, 2025 and December 31, 2024.

 

Recent Accounting Pronouncements

 

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. The amendments in this ASU require disclosures, on an annual and interim basis, of significant segment expenses that are regularly provided to the chief operating decision maker (“CODM”), as well as the aggregate amount of other segment items included in the reported measure of segment profit or loss. This ASU requires that a public entity disclose the title and position of the CODM and an explanation of how the CODM uses the reported measure(s) of segment profit or loss in assessing segment performance and deciding how to allocate resources. This ASU is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years, with early adoption permitted. The amendments in this ASU should be applied retrospectively to all prior periods presented in the financial statements. The Company adopted the ASU and determined that its adoption did not have a material impact on the Company’s financial statements and related disclosures. As defined in the ASU, operating segments are components of an enterprise about which discrete financial information is regularly provided to the CODM in making decisions on how to allocate resources and assess performance for the organization. The Company operates and manages its business as one reportable and operating segment. The Company’s CODM is the Chief Executive Officer. The Company’s CODM reviews operating results to make decisions about allocating resources and assessing performance for the entire Company.

  

The Company does not believe that other standards, which have been issued but are not yet effective, will have a significant impact on its financial statements.

 

NOTE 4 – ASSET PURCHASE AGREEMENTS

 

On February 17, 2026, the Company entered into an Asset Purchase Agreement pursuant to which the Company acquired various proprietary assets and intellectual property for 12,000,000 restricted shares of common stock valued at $7,932,000.

 

The Company evaluated the Asset Purchase Agreement in accordance with ASC 805 – Business Combinations which notes the threshold requirements of a business combination that includes the expanded definition of a “business” and defines elements that are to be present to be determined whether an acquisition of a business occurred. No “activities” of the acquiree were acquired. Instead, the Company obtained control of a set of inputs (the acquired assets). Thus, the Company determined agreement is an acquisition of assets, not an acquisition of a business in accordance with ASC 805. Management evaluated the assets and determined the value to $7,932,000 as of March 31, 2026.

 

 
11

Table of Contents

 

NOTE 5 – NOTES PAYABLE

 

Promissory notes payable as of March 31, 2026 and December 31, 2025 consists of the following:

 

March 31, 2026

 

 

December 31, 2025

 

$

73,228

 

 

$73,228

 

 

2,500

 

 

 

2,500

 

 

20,000

 

 

 

20,000

 

 

4,571

 

 

 

4,571

 

 

763

 

 

 

763

 

 

7,341

 

 

 

7,341

 

 

2,500

 

 

 

2,500

 

 

5,000

 

 

 

5,000

 

 

13,000

 

 

 

13,000

 

 

8,000

 

 

 

8,000

 

 

976

 

 

 

976

 

 

12,000

 

 

 

12,000

 

 

3,500

 

 

 

3,500

 

 

5,000

 

 

 

5,000

 

 

6,123

 

 

 

6,123

 

 

5,000

 

 

 

5,000

 

 

12,000

 

 

 

12,000

 

 

1,341

 

 

 

1,341

 

 

1,498

 

 

 

1,498

 

 

5,300

 

 

 

5,300

 

 

3,000

 

 

 

3,000

 

 

1,791

 

 

 

1,791

 

 

7,500

 

 

 

7,500

 

 

4,500

 

 

 

4,500

 

 

668

 

 

 

668

 

 

6,500

 

 

 

6,500

 

 

3,113

 

 

 

3,113

 

 

250

 

 

 

250

 

 

6,500

 

 

 

6,500

 

 

10,000

 

 

 

10,000

 

 

2,265

 

 

 

2,265

 

 

980

 

 

 

980

 

 

10,000

 

 

 

10,000

 

 

3,874

 

 

 

3,874

 

 

3,500

 

 

 

3,500

 

 

5,000

 

 

 

5,000

 

 

3,500

 

 

 

3,500

 

 

1,832

 

 

 

1,832

 

 

742

 

 

 

742

 

 

7,148

 

 

 

7,148

 

 

374

 

 

 

-

 

 

28,010

 

 

 

-

 

$

300,688

 

 

$272,304

 

 

During the three months ended March 31, 2026, the Company has issued various promissory notes amounting to $28,384 for general operating purposes. The notes carry an interest rate of 10% and are due upon demand.

  

During the three months ended March 31, 2026 and 2025, the Company recorded interest expense related to these notes of $5,488 and $4,547, respectively.

 

 
12

Table of Contents

 

NOTE 6 – CONVERTIBLE NOTES PAYABLE

 

Convertible notes payable as of March 31, 2026 and December 31, 2025 consists of the following:

 

March 31, 2026

 

 

December 31, 2025

 

$

15,487

 

 

$15,487

 

 

11,103

 

 

 

11,103

 

 

8,000

 

 

 

8,000

 

$

34,591

 

 

$34,591

 

 

During the three months ended March 31, 2026 and 2025, the Company recorded interest expense of $1,771 and  $1,771, respectively.

 

NOTE 7 – RELATED PARTY TRANSACTIONS

 

As of March 31, 2026 and December 31, 2025, the Company had notes due to its majority shareholder, Kevin Rodan Levy, of $88,042 and $88,042, respectively. The notes carry an interest rate of 10% and are due upon demand.

 

During the three months ended March 31, 2026 and 2025, the Company recorded interest expense related to these notes of $2,171 and $2,171, respectively.

 

NOTE 8 – COMMITMENTS AND CONTINGENCIES

 

From time to time, the Company may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm business. Management is currently not aware of any such legal proceedings or claims that could have, individually or in the aggregate, a material adverse effect on our business, financial condition, or operating results.

 

NOTE 9 – STOCKHOLDERS’ EQUITY

 

As of  March 31, 2026 and December 31, 2025, the Company had 56,134,795 and 44,296,895 shares of common stock issued and outstanding.

 

On July 1, 2024, the Company’s Board of Directors approved a One for Four Hundred Fifty (1-for-450) Reverse Stock Split of the issued and outstanding shares of Common Stock. The financial statements have been retroactively restated to reflect the split.

 

On October 12, 2023, the Board of Directors authorize an amendment to the articles of Incorporation to specifically increase the authorized shares to One Billion (1,000,000,000), consisting of; (i) Seven Hundred Million (700,000,000) shares of Common Stock, par value $0.0001 per share, Three Hundred Million (300,000,000) shares of preferred stock, par value $0.0001 per share which are issuable in one or more Series; to designate 10,000,000 preferred shares as Series A Preferred Stock and, (iv) to designate 10,000,000 preferred shares as Series B Preferred Stock.

 

 
13

Table of Contents

 

 

The Series A Preferred Stock shall rank senior to all Common Stock and any other class of securities that is specifically designated as junior to the Series A Preferred Stock however, does not have the right to vote. The Series A Preferred Stock is entitled to receive dividends from the Issuance Date thereof at the annual rate of three percent (3%) of the Original Issue Price, payable by the Board of Directors in quarterly installments. The Dividends shall cease to accrue on shares of Series A Preferred Stock on the date of any Conversion, as set forth herein. Each share of Series A Preferred Stock shall be convertible at the option of the holder after the One (1) Year anniversary of the Issuance Date, into a number of shares of Common Stock determined by dividing (i) the total number of Series A Preferred Shares being converted by (ii) the Conversion Price (the “Conversion Ratio”). The conversion price for the Series A Preferred Stock (the “Conversion Price”) shall be equal to $1.00 per share, which may be adjusted from time to time as hereinafter provided.

  

Series B Preferred Stock shall rank senior to all Common Stock and pari passu to the Series A Preferred Stock. Each share of Series B Preferred Stock shall be convertible at the option of the Holder thereof at any time, and from time to time, from and after the One (1) Year anniversary of the Issuance Date, into a number of shares of Common Stock determined by dividing (i) the total number of Series B Preferred Shares being converted by (ii) the Conversion Price The conversion price for the Series B Preferred Stock (the “Conversion Price”) shall be equal to $1.00 per share, which may be adjusted from time to time.  Series B Preferred Stock shall not have the right to vote on any matters, questions, or proceedings of this Corporation. Holders of the Series B Preferred Stock must hold their Preferred shares for a period one (1) year from the Issuance Date prior to converting their Series B Preferred Shares to Common Shares.

 

Following the expiration of the Hold Period, the Corporation shall issue to the Holders bonus shares of the Corporation’s Common Stock in such amount to be the number of Series B Preferred held by each Holder by (ii)”). The Board of Directors shall have the authority, in its discretion, to grant the Bonus Shares to the Holders. Each Bonus Share shall constitute a transfer of a restricted Common Share to the Holder, without other payment therefor, as a bonus to the Holder.

 

On February 17, 2026, a shareholder returned and the Company cancelled 162,100 shares of common stock for no consideration.

 

On March 10, 2026, the Company issued 12,000,000 shares of common stock valued at $7,932,000 for certain intangible assets.

 

NOTE 10 – SUBSEQUENT EVENTS

 

In accordance with ASC Topic 855-10, the Company has analyzed its operations subsequent to March 31, 2026 through the date these financial statements were available to be issued and has identified the following material subsequent events:

 

On April 28, 2026, the Company filed a Certificate of Amendment to its Articles of Incorporation with the Nevada Secretary of State, changing the Company's corporate name from "Catalyst Crew Technologies Corp." to "LataMed AI Corp." The name change became effective upon filing.

 

On May 6, 2026, the Board of Directors of the Company approved the designation of a new series of preferred stock designated as the "Series C Voting Preferred Stock" and filed a Certificate of Designation with the Nevada Secretary of State. The principal terms include: (i) 5,000,000 authorized shares; (ii) voting rights of twenty (20) votes per share, voting together with the Company's common stock as a single class on all matters submitted to stockholders; (iii) non-convertible; (iv) liquidation preference senior to Common Stock and pari passu with any other series of Preferred Stock; and (v) non-redeemable. Protective provisions require approval of holders of a majority of outstanding Series C Preferred Stock prior to, among other things, creating or issuing any class of capital stock ranking senior to the Series C Preferred Stock, amending the terms of the Series C Preferred Stock in a manner adverse to its holders, or liquidating, dissolving, or winding up the Company.

 

Other than the foregoing, the Company has determined that it does not have any other material subsequent events to disclose in these financial statements.

 

 
14

Table of Contents

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

 

FORWARD-LOOKING STATEMENTS

 

The following discussion may contain forward-looking statements regarding the Company, its business prospects and its results of operations that are subject to certain risks and uncertainties posed by many factors and events that could cause the Company’s actual business, prospects and results of operations to differ materially from those that may be anticipated by such forward-looking statements. These forward-looking statements reflect our view only as of the date of this report. The Company cannot guarantee future results, levels of activity, performance, or achievement. The Company does not undertake any obligation to update or correct any forward-looking statements.

 

Business Update 

 

During the quarter ended March 31, 2026, the Company undertook a strategic transition toward the development of artificial intelligence-enabled healthcare technology solutions and related healthcare services infrastructure focused on Latin America.

 

On February 17, 2026, the Company entered into an Asset Purchase Agreement pursuant to which it acquired certain proprietary healthcare technology assets and intellectual property relating to an artificial intelligence-enabled healthcare analytics platform and a technology-enabled healthcare services coordination platform. The acquired assets include technologies intended to support data-driven healthcare analytics, patient monitoring, telehealth infrastructure, and related healthcare applications.

 

In connection with the Company’s strategic transition, the Company also established and organized operations through its wholly-owned Venezuelan subsidiary, Inversiones Long 33, C.A., which is intended to serve as the Company’s operating entity in Venezuela and support its broader Latin American business strategy.

 

During April 2026, certain intellectual property assets acquired by the Company were assigned to the subsidiary as part of an internal operational reorganization. Prior to such assignment, the subsidiary had no material operations, assets, liabilities, or standalone financial history.

 

Current activities are focused on organizational development, operational structuring, technology evaluation, regulatory planning, and business development initiatives related to the Company’s intended healthcare technology platform and services model.

 

Results of Operations for the Three Months Ended March 31, 2026 and 2025

 

Revenues

 

We had no revenue for three months ended March 31, 2026 and 2025.

 

Operating Expenses

 

Operating expenses increased to $43,384 for the three months ended March 31, 2026, from $15,967 for the same period ended March 31, 2025.

 

The increase in operating expenses is the result of additional professional fees incurred during the three months ended March 31, 2026.

 

Other Income (Expenses)

 

We had other expenses of $9,429 for the three months ended March 31, 2026, as compared with other expenses of $8,488 for the three months ended March 31, 2025. The increase in other expenses is the result of increased interest expense incurred during the three months ended March 31, 2026.

 

Net Loss

 

We recorded a net loss of $52,813 for the three months ended March 31, 2026, as compared with a net loss of $24,455 for the three months ended March 31, 2025.

 

 
15

Table of Contents

 

Liquidity and Capital Resources

 

Going concern – The accompanying financial statements have been prepared in US dollars and in accordance with accounting principles generally accepted in the United States (“GAAP”) on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. During three months ended March 31, 2026, the Company incurred net losses of $52,813 and accumulated deficits of $29,653,599. These conditions raise substantial doubt about the Company's ability to continue as a going concern.

 

As of March 31, 2026, we had total current assets of $0 and total assets in the amount of $7,824,000. Our total current liabilities as of March 31, 2026 were $683,673. We had a working capital deficit of $683,673 as of March 31, 2026, compared with a working capital deficit of $630,860 as of December 31, 2025.

 

Operating activities used $28,384 in cash for the three months ended March 31, 2026, as compared with $19,015 used for the three months ended March 31, 2025. Our negative operating cash flows for 2026 and 2025 was largely the result of our net loss for those quarters, mainly offset by changes in operating assets and liabilities.

 

We used no cash in investing activities for the three months ended March 31, 2026 and 2025.

 

Cash flow provided from financing activities was $28,384 for the three months ended March 31, 2026, as compared with $19,015 provided by cash flows for financing activities during the three months ended March 31, 2025.

 

Based upon our current financial condition, we do not have sufficient cash to operate our business at the current level for the next twelve months. We intend to fund operations through increased sales and debt and/or equity financing arrangements, which may be insufficient to fund expenditures or other cash requirements. We plan to seek additional financing in a private equity offering to secure funding for operations. There can be no assurance that we will be successful in raising additional capital.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

As a smaller reporting company, we are not required to provide the information required by this Item.

 

Item 4. Controls and Procedures

  

Evaluation of Disclosure Controls and Procedures

 

Under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, the Company conducted an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures, as such term is defined under Rule 13a-15(e) promulgated under the Exchange Act, as of March 31, 2026. Based on this evaluation, management concluded that our financial disclosure controls and procedures were not effective so as to timely record, process, summarize and report financial information required to be included on our SEC reports due to the Company’s limited internal resources and lack of ability to have multiple levels of transaction review. However, as a result of our evaluation and review process, management believes that the financial statements and other information presented herewith are materially correct.

  

Change in Internal Control Over Financial Reporting

 

The Company has not made any change in our internal control over financial reporting during the period ended March 31, 2026.

 

 
16

Table of Contents

  

PART II. OTHER INFORMATION

 

 

Item 5. Other Information.

 

During the quarter ended March 31, 2026, no director or officer of the Company adopted, modified, or terminated any Rule 10b5-1 trading arrangement or any non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K.

 

 
17

Table of Contents

 

ITEM 6 - EXHIBITS

Number Description of Exhibit

 

3.1

 

Articles of Incorporation, as amended (1)

3.2

 

Certificate of Amendment to the Articles of Incorporation of LataMed AI Corp.(2)

3.3

 

Certificate of Change Reflecting Reverse Stock Split(2)

3.4

 

Bylaws(1)

31.1

 

Certification of Principal Executive Officer Pursuant to Rule 13A-14(A) Under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.**

31.2

 

Certification of Principal Financial and Accounting Officer Pursuant to Rule 13A-14(A) Under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.**

32.1

 

Certification pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002. **

32.2

 

Certification pursuant to Securities Exchange Act of 1934 Rule 13a-14(b) or 15d-14(b) and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002. **

101.INS

 

Inline XBRL Instance Document

101.SCH

 

Inline XBRL Taxonomy Extension Schema

101.CAL

 

Inline XBRL Taxonomy Extension Calculation Linkbase

101.DEF

 

Inline XBRL Inline XBRL Taxonomy Extension Definition Linkbase

101.LAB

 

Inline XBRL Inline XBRL Taxonomy Extension Labels Linkbase

101.PRE

 

Inline XBRL Taxonomy Extension Presentation Linkbase

104

 

Cover Page Interactive Data File (Embedded within the Inline XBRL document)

 

 

(1)

Filed with the SEC on February 5, 2024 as an exhibit to our Registration Statement on Form 10-12G

 

(2)

Filed with the SEC on August 16, 2024 as an exhibit to Current Report on Form 8-K

 

**

Filed herewith

 

# The XBRL related information in Exhibit 101 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability of that section and shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.

 

 
18

Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

LataMed AI Corp.

 

 

 

 

 

Date: May 20, 2026

By:

/s/ Kevin Rodan Levy

 

 

Name:

Kevin Rodan Levy

 

 

Title:

Chief Executive Officer (Principal Executive Officer)

 

 

Date: May 20, 2026

By:

/s/ Carlos Pena

 

 

Name:

Carlos Pena

 

 

Title:

Chief Financial Officer (Principal Financial and Accounting Officer)

 

 

 
19

 

Source: View Original Filing on SEC EDGAR

FAQ

What were LataMed AI Corp. (CCTC) revenue and net loss for Q1 2026?

LataMed AI Corp. generated no revenue in Q1 2026 and recorded a net loss of $52,813. The prior-year quarter also had no revenue and a net loss of $24,455, underscoring that the company remains in an early-stage, pre-revenue development phase.

What is LataMed AI Corp.’s new business focus after its recent transition?

The company is pivoting to AI-enabled healthcare technology and related services in Latin America. It acquired proprietary healthcare analytics and coordination platforms and organized a Venezuelan subsidiary, Inversiones Long 33, C.A., to support data-driven healthcare analytics, patient monitoring, telehealth infrastructure, and related applications.

What is LataMed AI Corp.’s financial position and going concern status?

As of March 31, 2026, the company had no cash, current liabilities of $683,673, and a working capital deficit of the same amount. With an accumulated deficit of $29,653,599, management states these conditions raise substantial doubt about its ability to continue as a going concern.

How is LataMed AI Corp. (CCTC) funding its operations in Q1 2026?

Operations were funded primarily through promissory notes. In Q1 2026, the company obtained $28,384 of new notes payable at a 10% interest rate, bringing total notes payable to $300,688, alongside $34,591 of convertible notes and $88,042 owed to its majority shareholder.

What major corporate actions and capital changes has LataMed AI Corp. undertaken?

The company executed a 1-for-450 reverse stock split and increased authorized capital to 1,000,000,000 shares. It also issued 12,000,000 common shares for intangible assets valued at $7,932,000 and later designated non-convertible Series C Voting Preferred Stock with twenty votes per share.

How effective are LataMed AI Corp.’s internal controls over financial reporting?

Management concluded disclosure controls and procedures were not effective as of March 31, 2026. The weakness stems from limited internal resources and the inability to implement multiple levels of transaction review, although management believes the financial statements presented are materially correct.